Alectinib Approved in China for ALK+ NSCLC

August 21, 2018 – The China National Drug Administration (CNDA) has approved alectinib for the treatment of patients with ALK-positive, advanced non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor. The approval was based on the primary analysis of the phase III ALEX study, in which frontline alectinib reduced the risk of disease progression or death by 53% versus crizotinib in patients with ALK- … (leggi tutto)